Hua Medicine – A Global Effort to Stop Diabetes

Diabetes has become a disaster with more than 400 million individuals Type 2 Diabetes (T2D) globally. Complications such as diabetic retinopathy, kidney disease and cardiovascular and cerebrovascular diseases pose enormous challenges to the global healthcare system, and global diabetes management costs have reached $800 billion.

Scientists and medical experts all over the world have worked together and developed many hypoglycemic drugs to treat diabetes. However, the key causes of T2D, insulin resisitance and pancreas islet dysfuntion, have still not been addressed successfully. T2D is a progressive disease, involving degeneration in pancreatic functions. We are still looking for new therapy with a more complete understanding of the disease mechanisms.

After over half a century has passed since it’s discovery, our understanding of the role of Glucokinase in human glucose homeostasis has been substantially enhanced. Based on the tremendous efforts of scientists at Hua Medicine, as well as leading physicians in China and all over the world, the first Glucokinase Activator (GKA) in phase III trials, Dorzagliatin, is expected to have topline results in Q4 2019, a significant step forward in T2D research.

The unique structure of Dorzagliatin means it will be the first GKA entering into phase III trials with good efficacy and safety data from phase II trial. Dorzagliatin has the potential to solve the root cause of T2D pathogenesis and to revitalize the function of the Beta-cell, a dream pursued for centuries by physicians. Patients may benefit from the treatment with delayed insulin use, delayed complications and better quality of life.

With 435 million T2D patients globally, it’s essential to classify the many undiagnosed patients around the world and to provide personalized treatment for better efficacy, improved safety, and reduced complications. There is a great potential for combination therapy involving dorzagliatin with other diabetic agents, and targeting different subtypes of T2D patients with various combination will make it a game changer in treating diabetes.

Glucokinase: 50 Years of Research – https://youtu.be/ddqqi-vSD7w
A New Kind of Glucokinase Activator – https://youtu.be/fwujcni7tiQ
Patient First: Clinical Trials in China – https://youtu.be/qNaWvA62BZw
A Global Effort to Stop Diabetes – https://youtu.be/U470u-u3HHk